Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by inthnoon Apr 17, 2024 1:39pm
47 Views
Post# 35994193

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Have a think!!

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Have a think!!
Ok NOTE and putting everything else aside for the moment, I have a serious question for you in regards to the options reporting.
As we already know , ONC management did not declare their Dec 13th 2023 options as either expired or exercised on sedi which is a requirement by law and the exchanges.
I contacted the company and they told me that they were in compliance and was able to find that the only way they can be in compliance and not declare their options is if indeed they are in a blackout period.

This is from one of their circulars which I found on sedar....

  1. This is the statement from the circular
The Stock Option Plan provides that if the expiration date of an Option occurs during a “blackout period” or within
five (5) business days after a blackout period, such expiration date shall be deemed to be extended to the date which is the tenth
  1. (10th) business day after the last day of the applicable blackout period.
So if the company is not in a blackout period as you suggest, would that then mean that they are not in compliance with sedi and tsx reporting rules and regulations....

Just curious as to your thoughts on this.

<< Previous
Bullboard Posts
Next >>